Silexion Therapeutics Statistics
Total Valuation
SLXN has a market cap or net worth of $4.44 million. The enterprise value is $20.30 million.
Important Dates
The next estimated earnings date is Thursday, November 21, 2024, before market open.
Earnings Date | Nov 21, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
SLXN has 8.32 million shares outstanding.
Shares Outstanding | 8.32M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.12 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.85
Current Ratio | 3.85 |
Quick Ratio | 3.64 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -452.67 |
Financial Efficiency
Return on equity (ROE) is -116.66% and return on invested capital (ROIC) is -73.07%.
Return on Equity (ROE) | -116.66% |
Return on Assets (ROA) | -62.13% |
Return on Capital (ROIC) | -73.07% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | -0.12 |
52-Week Price Change | n/a |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 30.39 |
Average Volume (20 Days) | 6,399,434 |
Short Selling Information
The latest short interest is 3,850, so 0.05% of the outstanding shares have been sold short.
Short Interest | 3,850 |
Short Previous Month | 4,315 |
Short % of Shares Out | 0.05% |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.98 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -1.36M |
Pretax Income | n/a |
Net Income | -1.36M |
EBITDA | -1.36M |
EBIT | -1.36M |
Earnings Per Share (EPS) | -$9.09 |
Full Income Statement Balance Sheet
Cash & Cash Equivalents | 788,000 |
Total Debt | n/a |
Net Cash | 788,000 |
Net Cash Per Share | $0.09 |
Equity (Book Value) | 696,000 |
Book Value Per Share | 4.67 |
Working Capital | 687,000 |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$794,000 and capital expenditures -$5,000, giving a free cash flow of -$799,000.
Operating Cash Flow | -794,000 |
Capital Expenditures | -5,000 |
Free Cash Flow | -799,000 |
FCF Per Share | -$0.10 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |